The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects

PURPOSE: Apixaban is often coadministered with treatments for cardiovascular comorbidities, which may lead to unintended drug–drug interactions (DDIs). The effects of apixaban on pharmacokinetics (PK) of multidose Lanoxin(®) (digoxin) and single-dose Tenormin(®) (atenolol) and the effects of single-...

Descripción completa

Detalles Bibliográficos
Autores principales: Frost, Charles, Song, Yan, Yu, Zhigang, Wang, Jessie, Lee, Lois S, Schuster, Alan, Pollack, Allyson, LaCreta, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327911/
https://www.ncbi.nlm.nih.gov/pubmed/28260951
http://dx.doi.org/10.2147/CPAA.S115687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327911/
https://www.ncbi.nlm.nih.gov/pubmed/28260951
http://dx.doi.org/10.2147/CPAA.S115687

Ejemplares similares